Stanley Capital Management LLC Buys Shares of 87,400 IQVIA Holdings Inc. $IQV

Stanley Capital Management LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 87,400 shares of the medical research company’s stock, valued at approximately $16,887,000. IQVIA comprises 2.2% of Stanley Capital Management LLC’s investment portfolio, making the stock its 20th biggest holding. Stanley Capital Management LLC owned about 0.05% of IQVIA as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Freedom LLC bought a new position in IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors bought a new stake in IQVIA during the first quarter valued at $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA during the 4th quarter worth about $27,000. Compass Financial Management LLC bought a new position in shares of IQVIA in the 2nd quarter worth about $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at about $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on IQV shares. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Mizuho boosted their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. TD Cowen boosted their price target on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, BMO Capital Markets boosted their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider W Richard Staub sold 5,500 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 in the last 90 days. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Down 0.1%

Shares of IQVIA stock opened at $259.97 on Wednesday. The stock has a market capitalization of $42.79 billion, a price-to-earnings ratio of 32.25, a P/E/G ratio of 2.21 and a beta of 1.18. The company’s 50 day moving average price is $216.59 and its 200-day moving average price is $188.02. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $261.88.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the previous year, the firm earned $2.81 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.